{
    "nct_id": "NCT04692493",
    "official_title": "A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)",
    "inclusion_criteria": "1. Patients with active, disabling RA (CDAI ≥10 and HAQ ≥0.5) despite the use/experience for ≥ 3 months of a TNFi-biologic OR discontinued the medication(s) due to intolerability or toxicity irrespective of treatment duration prior to the first dose of study drug ;\n2. If receiving glucocorticoids (≤10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥2 weeks prior to randomization; and\n3. Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD.\n\nParticipants will be allowed to continue their conventional synthetic DMARD (csDMARD) therapy if they had been using it for ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide (TNFi-biologic and tsDMARD) through insurance plan or a patient assistance program/plan.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic\n2. Prior treatment with targeted synthetic DMARD\n3. Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization;\n4. History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD;\n5. Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry;\n6. Live vaccine within 90 days of study entry;\n7. Acute or chronic infections with parenteral antibiotics or hospitalization (including tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis)) within 1 month or oral antibiotics within 2 weeks of study entry;\n8. History of HIV or any opportunistic infection;\n9. New York Heart Association Class III or IV heart failure;\n10. Latent TB for which anti-tubercular treatment has not been started;\n11. Untreated Hepatitis B or C infection;\n12. History of deep venous thrombosis or pulmonary embolism; or\n13. Pregnant or nursing women; or\n14. History of herpes zoster or shingles.",
    "miscellaneous_criteria": ""
}